sb 203580 has been researched along with alendronate in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (alendronate) | Trials (alendronate) | Recent Studies (post-2010) (alendronate) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 4,096 | 731 | 1,724 |
| Protein | Taxonomy | sb 203580 (IC50) | alendronate (IC50) |
|---|---|---|---|
| Chain A, farnesyl pyrophosphate synthase | Trypanosoma cruzi | 147 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.7523 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaji, H; Kawao, N; Okada, K; Okumoto, K; Tamura, Y; Yano, M | 1 |
1 other study(ies) available for sb 203580 and alendronate
| Article | Year |
|---|---|
Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Topics: Activin Receptors, Type I; Alendronate; Alkaline Phosphatase; Animals; Benzamides; Calcium; Cell Line; Collagen Type I; Dioxoles; Imidazoles; Male; Mice; Mice, Nude; Mutation; Myoblasts; Myositis Ossificans; Ossification, Heterotopic; Osteoclasts; Peptides; Phosphorus; Pyridines | 2016 |